Research Paper released over the weekend:
Clinical and microbiological effect of a combination of hydroxychloroquine and
azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study
Running title: Hydroxychloroquine-Azithromycin and COVID-19
Abstract
We need an effective treatment to cure COVID-19 patients and to decrease the virus carriage
duration. In 80 in-patients receiving a combination of hydroxychloroquine and azithromycin
we noted a clinical improvement in all but one 86 year-old patient who died, and one 74 year
old patient still in intensive care unit. A rapid fall of nasopharyngeal viral load tested by
qPCR was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient
respiratory samples were negative in 97.5% patients at Day5. This allowed patients to rapidly
de discharge from highly contagious wards with a mean length of stay of five days. We
believe other teams should urgently evaluate this cost-effective therapeutic strategy, to both
avoid the spread of the disease and treat patients as soon as possible before severe respiratory
irreversible complications take hold.
Regards
SP
- Forums
- World Politics
- US FDA drug championed by Donald Trump
US FDA drug championed by Donald Trump, page-51
-
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online